| $337M | ||
| $259M | ||
| $100M | ||
| $79M | ||
| $60M | ||
| $58M |
Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The company is also developing NC410, which is in Phase I for novel immunomedicine designed to block immune suppression mediated by an immune modulator called Leukocyte-Associated Immunoglobulin-like Receptor 1; NC762, an immunomedicine targeting a molecule called human B7 homolog 4 protein, or B7-H4; and NC525, a novel LAIR-1 antibody which is in Preclinical trails that targets acute myeloid leukemia, blast cells, and leukemic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. The company has a license agreement with Yale University. NextCure, Inc. was incorporated in 2015 and is headquartered in Beltsville, Maryland.
Over the last 12 months, insiders at NextCure, Inc. have bought $0 and sold $0 worth of NextCure, Inc. stock.
On average, over the past 5 years, insiders at NextCure, Inc. have bought $0 and sold $0 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 150,000 shares for transaction amount of $5.51M was made by Sofinnova Venture Partners IX, L.P. (10 percent owner) on 2019‑11‑15.
| 2019-11-15 | Sofinnova Venture Partners IX, L.P. | 10 percent owner | 150,000 0.9742% | $36.75 | $5.51M | -7.91% | ||
| 2019-05-13 | ORBIMED ADVISORS LLC | 700,000 4.0096% | $15.00 | $10.5M | +82.16% | |||
| 2019-05-13 | Khuong Chau Quang | director | 350,000 2.0048% | $15.00 | $5.25M | +82.16% | ||
| 2019-05-13 | Sofinnova Venture Partners IX, L.P. | 10 percent owner | 400,000 2.2912% | $15.00 | $6M | +82.16% | ||
| 2019-05-13 | SHANNON TIMOTHY M | director | 50,000 0.2864% | $15.00 | $750,000 | +82.16% | ||
| 2019-05-13 | CANAAN X L.P. | 10 percent owner | 50,000 0.2864% | $15.00 | $750,000 | +82.16% | ||
| 2019-05-13 | Xu Stella | director | 125,000 0.716% | $15.00 | $1.88M | +82.16% |
| ORBIMED ADVISORS LLC | 2711013 9.6649% | $13.07M | 1 | 0 | ||
| Khuong Chau Quang | director | 2711013 9.6649% | $13.07M | 1 | 0 | |
| Sofinnova Venture Partners IX, L.P. | 10 percent owner | 2671856 9.5253% | $12.88M | 2 | 0 | <0.0001% |
| SHANNON TIMOTHY M | director | 2254442 8.0372% | $10.87M | 1 | 0 | |
| CANAAN X L.P. | 10 percent owner | 2254442 8.0372% | $10.87M | 1 | 0 | |
| Xu Stella | director | 1103570 3.9343% | $5.32M | 1 | 0 |
$5,558,275 | 76 | -5.88% | $149.59M | |
$18,752,549 | 33 | -28.39% | $142.5M | |
$6,915,275 | 21 | -32.61% | $121.53M | |
$294,424,120 | 20 | 1.33% | $129.54M | |
$1,351,643 | 19 | 46.45% | $144.81M | |
$448,999,793 | 15 | -19.99% | $129.85M | |
$73,968,137 | 12 | -34.52% | $124.51M | |
$9,999,920 | 10 | -40.03% | $123.58M | |
$456,220 | 9 | 34.12% | $135.75M | |
$22,090,972 | 7 | -3.49% | $138.1M | |
$478,647 | 7 | 69.41% | $118.23M | |
$68,692,148 | 6 | -39.10% | $124.75M | |
$63,981 | 5 | -11.55% | $138.28M | |
$556,839 | 5 | 13.42% | $143.43M | |
$59,900 | 4 | -5.37% | $120.68M | |
$19,175,155 | 2 | 40.00% | $121.99M | |
$9,999,990 | 2 | 25.53% | $139.76M | |
NextCure, Inc. (NXTC) | $5,512,500 | 1 | -7.91% | $135.2M |
$300,016 | 1 | -50.33% | $141.12M |
| Increased Positions | 0 | 0% | 0 | 0% |
| Decreased Positions | 0 | 0% | 0 | 0% |
| New Positions | 0 | New | 0 | New |
| Sold Out Positions | 0 | Sold Out | 0 | Sold Out |
| Total Postitions | 0 | 0% | 0 | 0% |
| Sofinnova Investments, Inc. | $1,184.00 | 9.54% | 2.67M | 0 | 0% | 2024-12-31 |
| Affinity Asset Advisors, Llc | $1,020.00 | 8.22% | 2.3M | 0 | 0% | 2024-12-31 |
| Citigroup Inc | $615.00 | 4.96% | 1.39M | +1M | New | 2024-12-31 |
| Orbimed Advisors Llc | $506.00 | 4.08% | 1.14M | 0 | 0% | 2024-12-31 |
| Vanguard Group Inc | $437.00 | 3.53% | 987,324 | 0 | 0% | 2024-12-31 |
| Tang Capital Management Llc | $310.00 | 2.5% | 700,000 | +47,614 | +7.3% | 2024-12-31 |
| Cable Car Capital, Lp | $273.00 | 2.2% | 615,878 | 0 | 0% | 2024-12-31 |
| Blackrock, Inc. | $247.00 | 1.99% | 556,686 | -170,893 | -23.49% | 2025-03-31 |
| Renaissance Technologies Llc | $230.00 | 1.86% | 519,300 | +113,300 | +27.91% | 2024-12-31 |
| Acadian Asset Management Llc | $216.00 | 1.74% | 488,440 | 0 | 0% | 2024-12-31 |